High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.
about
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommendedA Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI].The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.Single or dual antiplatelet therapy after PCI.Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation.Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes.Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis.Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
P2860
Q34990721-C292D1AE-3CDE-4B40-AB6D-CFBF6937CDBFQ35870016-94CE8FA8-4602-470F-B63F-44AFBC23A254Q38790876-104B57CC-82C9-444D-96AD-77D96DF5FEAFQ38838327-F7E27CE8-E1C8-40D3-8185-E08E59399639Q38958862-665124B5-26D4-482B-831A-F3DD238A9D62Q38970275-F6555975-CDB3-4CE3-A23C-1A9D9C092C92Q40908174-5CFBBC3B-13D3-40E0-A4EF-2DAC7D36F66BQ48737764-983E5352-79E0-4171-9523-469CA982B5C4Q50868428-D8059985-2409-40B2-AD3D-EF696867021BQ55473805-2C8F1466-ABC4-435E-B300-E393FA1C5DB7Q58768916-57577AA3-81E1-4D90-AEFC-65F82B76C0F7
P2860
High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
High on-treatment platelet rea ...... analysis of the ARCTIC study.
@en
type
label
High on-treatment platelet rea ...... analysis of the ARCTIC study.
@en
prefLabel
High on-treatment platelet rea ...... analysis of the ARCTIC study.
@en
P2093
P50
P1433
P1476
High on-treatment platelet rea ...... analysis of the ARCTIC study.
@en
P2093
ARCTIC Investigators
Christophe Pouillot
Christophe Saint-Etienne
Didier Carrié
Eric Van Belle
Eric Vicaut
Grégoire Rangé
Hélène Rousseau
Jacques Monségu
Jean-Louis Bonnet
P304
P356
10.1161/CIRCULATIONAHA.113.007524
P407
P577
2014-04-09T00:00:00Z